Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals

AIDS

Volumn 22, Issue 12, 2008, Pages 1425-1431

  Irlbeck, David M ^a   Amrine Madsen, Heather ^a   Kitrinos, Kathryn M ^a   Labranche, Celia C ^a   Demarest, James F ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Chemokines; Envelope proteins; HIV drug resistance; HIV 1; Receptor; Tropism; Virus cell interaction

Indexed keywords

APLAVIROC; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 160; 873140 COMPOUND; BENZOIC ACID DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PIPERAZINE DERIVATIVE; SPIRO COMPOUND; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ASSAY; CLINICAL ARTICLE; CLONE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; PHYLOGENY; PLASMA; PRIORITY JOURNAL; VIRUS ISOLATION; ANTIVIRAL RESISTANCE; BLOOD; CD4 LYMPHOCYTE COUNT; CELL CULTURE; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MOLECULAR EVOLUTION; PHYSIOLOGY; PLANT GROWTH; VIROLOGY;

BENZOATES; CD4 LYMPHOCYTE COUNT; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EVOLUTION, MOLECULAR; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PHYLOGENY; PIPERAZINES; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; SPIRO COMPOUNDS; TROPISM;

EID: 49849083022     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830184ba     Document Type: Article

References (13)

1. Stalmeijer EH, van Rij RP, Boeser-Nunnink B, Visser JA, Naard-ing MA, Schols D, et al. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J Virol 2004; 78:2722-2728.
2. Koot M, Keet IPM, Vos AHV, de Goede REY, Roos MTL, Coutinho RA, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4R cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-688.
3. Moyle GJ, Wildfire A, Mandalia S, Howard M, Goodrich J, Whitcomb J, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-872.
4. Brumme Z, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, et a/. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-474.
5. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, et a/. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 co-receptor tropism. Antimicrob Agents Chemother 2007; 51:566-575.
6. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et a/. A novel phenotypic drug susceptibility assay for human immunodeficiency type 1. Antimicrob Agents Chemother 2000; 44:920-928.
7. De Jong J, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing pheno-type: analysis of single amino acid substitution. J Virol 1992; 66:6777-6780.
8. FouchierRA, BrouwerM, Broersen SM, Schuitemaker H. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol 1995; 33:906-911.
9. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swan-strom R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002; 76:3852-3864.
10. Toma J, Whitcomb J, Fransen S, Reeves J, Parkin N, Petropoulos C, et al. Differential co-receptor use by dual-tropic HIV-1 envelops impacts co-receptor inhibitor susceptibility. Antivir Ther 2007; 12:S113.
11. Petropolous CJ, Huang W, Toma J, Fransen S, Bonhoeffer S, Whitcomb JM. Resistance to HIV-1 entry inhibitors may occur by multiple molecular mechanisms. Antivir Ther 2004; 9:S25.
12. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosely M, Stockdale M, et a/. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-2371.
13. Landovitz R, Faetkenhauer G, Hoffmann C, Horst H, Strizki J, Whitcomb J, et al. Characterization of susceptibility profiles for the CCR5 antagonist vicriviroc in treatment-naive HIV-infected subjects. Antivir Ther 2006; 11:S23.